DOI QR코드

DOI QR Code

Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51

  • Ryu, Hee Jung (Department of Rheumatology, Gachon University Gil Medical Center) ;
  • Seo, Mi Ryoung (Department of Rheumatology, Gachon University Gil Medical Center) ;
  • Choi, Hyo Jin (Department of Rheumatology, Gachon University Gil Medical Center) ;
  • Baek, Han Joo (Department of Rheumatology, Gachon University Gil Medical Center)
  • 투고 : 2016.03.26
  • 심사 : 2016.10.23
  • 발행 : 2018.09.01

초록

Background/Aims: The clinical manifestations of Behcet disease (BD) have been reported to differ according to country, region, and race. Gender, onset age, and human leukocyte antigen (HLA)-B51 have also been known as the factors that influence the clinical features of BD. The aim of this study is to investigate the clinical phenotypes of Korean patients who visited the rheumatology clinic with BD with respect to gender, onset age, and HLA-B51. Methods: Total 193 Korean patients (129 females and 64 males) fulfilling the international criteria for BD were retrospectively assessed. Results: The mean age at disease onset and disease duration of the BD patients were $32.2{\pm}11.1$ and $14.2{\pm}9.3$ years, retrospectively. Females suffered more frequently from genital ulcers (90.7% vs. 75.0%, p < 0.01), peripheral arthritis (67.4% vs. 43.8%, p < 0.01), and inf lammatory low back pain (38.8% vs. 23.4%, p = 0.03) than males, while skin involvement was more frequent in males than in females (90.6% vs. 75.2%, p = 0.01). The patients with late onset of BD (> 40 years) suffered from neurologic involvement (15.9% vs. 4.2%, p = 0.007) more frequently than those with early onset of BD. The patients with HLA-B51 showed earlier onset of disease than without HLA-B51 ($28.3{\pm}11.4years$ vs. $33.8{\pm}11.6years$, p = 0.02) and the neurologic and gastrointestinal involvements were more frequent in the patients without HLA-B51 than with HLA-B51 (17.2% vs. 2.5%, p = 0.02 and 20.7% vs. 2.5%, p = 0.01, respectively). Conclusions: The clinical phenotypes in Korean patients with BD may be influenced by gender, onset age and HLA-B51.

키워드

과제정보

연구 과제 주관 기관 : Gachon University Gil Medical Center

참고문헌

  1. Davatchi F, Shahram F, Chams C, Chams H, Nadji A. Behcet's disease. Acta Med Iran 2005;43:233-242.
  2. Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH. Epidemiology of Behcet disease. Ocul Immunol Inflamm 2012;20:324-335. https://doi.org/10.3109/09273948.2012.723112
  3. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's disease. Semin Arthritis Rheum 1998;27:197-217. https://doi.org/10.1016/S0049-0172(98)80001-2
  4. Onder M, Gurer MA. The multiple faces of Behcet's disease and its aetiological factors. J Eur Acad Dermatol Venereol 2001;15:126-136. https://doi.org/10.1046/j.1468-3083.2001.00251.x
  5. Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet's disease: from East to West. Clin Rheumatol 2010;29:823-833. https://doi.org/10.1007/s10067-010-1430-6
  6. Krause I, Mader R, Sulkes J, et al. Behcet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 2001;28:1033-1036.
  7. Rozenbaum M, Boulman N, Slobodin G, et al. Behcet disease in adult Druzes in north Israel: the influence of ethnic origin on disease expression and severity. J Clin Rheumatol 2007;13:124-127. https://doi.org/10.1097/RHU.0b013e3180645878
  8. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on patients with Behcet's disease in Korea. J Korean Med Sci 2003;18:231-235. https://doi.org/10.3346/jkms.2003.18.2.231
  9. Shang Y, Han S, Li J, Ren Q, Song F, Chen H. The clinical feature of Behcet's disease in Northeastern China. Yonsei Med J 2009;50:630-636. https://doi.org/10.3349/ymj.2009.50.5.630
  10. Davatchi F, Shahram F, Chams C, et al. The influence of gender on the frequency of clinical symptoms in Behcet's disease. Adv Exp Med Biol 2003;528:65-66.
  11. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 2003;42:346-351. https://doi.org/10.1046/j.1365-4362.2003.01741.x
  12. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheumatol 2003;21(4 Suppl 30):S19-S26.
  13. Saricaoglu H, Karadogan SK, Bayazit N, Yucel A, Dilek K, Tunali S. Clinical features of late-onset Behcet's disease: report of nine cases. Int J Dermatol 2006;45:1284-1287. https://doi.org/10.1111/j.1365-4632.2006.02921.x
  14. Tsai J, Chen GS, Lu YW, Wu CS, Lan CC. Late-onset Behcet's disease does not correlate with indolent clinical course: report of seven Taiwanese patients. J Eur Acad Dermatol Venereol 2008;22:596-600. https://doi.org/10.1111/j.1468-3083.2007.02556.x
  15. Sungur G, Hazirolan D, Hekimoglu E, Kasim R, Duman S. Late-onset Behcet's disease: demographic, clinical, and ocular features. Graefes Arch Clin Exp Ophthalmol 2010;248:1325-1330. https://doi.org/10.1007/s00417-010-1399-5
  16. Hazirolan D, Sungur G, Duman S. Demographic, clinical, and ocular features in patients with late-onset Behcet disease. Ocul Immunol Inflamm 2012;20:119-124. https://doi.org/10.3109/09273948.2012.655882
  17. Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study. Br J Dermatol 2007;157:901-906. https://doi.org/10.1111/j.1365-2133.2007.08116.x
  18. Hamuryudan V, Hatemi G, Tascilar K, et al. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010;49:173-177. https://doi.org/10.1093/rheumatology/kep350
  19. Hamzaoui A, Jaziri F, Ben Salem T, et al. Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Med Iran 2014;52:748-751.
  20. Wallace GR. HLA-B*51 the primary risk in Behcet disease. Proc Natl Acad Sci U S A 2014;111:8706-8707. https://doi.org/10.1073/pnas.1407307111
  21. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 2012;51:887-900. https://doi.org/10.1093/rheumatology/ker428
  22. Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH. HLA-B51 and its allelic types in association with Behcet's disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol 2001;19(5 Suppl 24):S31-S35.
  23. Hamzaoui A, Houman MH, Massouadia M, et al. Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet's disease in Tunisian patients. Eur J Intern Med 2012;23:347-349. https://doi.org/10.1016/j.ejim.2011.12.011
  24. International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28:338-347. https://doi.org/10.1111/jdv.12107
  25. Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784-788. https://doi.org/10.1136/ard.2008.101501
  26. Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behcet's disease: international consensus recommendations. J Neurol 2014;261:1662-1676. https://doi.org/10.1007/s00415-013-7209-3
  27. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-1080.
  28. Behcet's Disease Research Committee of Japan. Behcet's disease guide to the diagnosis of Behcet's disease (1972). Jpn J Ophthalmol 1974;18:291-294.
  29. Davatchi F, Shahram F, Nadji A, et al. Performance of existing diagnosis/classification criteria for Behcet's disease in Iranian patients: analysis of 5666 patients and 2406 controls. APLAR J Rheum 2006;9:238-243. https://doi.org/10.1111/j.1479-8077.2006.00207.x
  30. Davatchi F, Sadeghi Abdollahi B, Shahram F, et al. Validation of the international criteria for Behcet's disease (ICBD) in Iran. Int J Rheum Dis 2010;13:55-60. https://doi.org/10.1111/j.1756-185X.2009.01455.x
  31. Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol 2007;26:555-560. https://doi.org/10.1007/s10067-006-0349-4
  32. Kotevoglu N. Coexistence of ankylosing spondylitis and Behcet's disease: two cases with atypical presentation and course. Scand J Rheumatol 2003;32:184-185. https://doi.org/10.1080/03009740310002551
  33. Cimen OB, Sahin G, Bicer A, Erdogan C. Behcet's syndrome coexisting with clinically occult ankylosing spondylitis. Z Rheumatol 2002;61:440-442. https://doi.org/10.1007/s00393-002-0319-4
  34. Yavuz S, Ozilhan G, Elbir Y, Tolunay A, Eksioglu-Demiralp E, Direskeneli H. Activation of neutrophils by testosterone in Behcet's disease. Clin Exp Rheumatol 2007;25(4 Suppl 45):S46-S51.
  35. Alpsoy E, Elpek GO, Yilmaz F, et al. Androgen receptor levels of oral and genital ulcers and skin pathergy test in patients with Behcet's disease. Dermatology 2005;210:31-35. https://doi.org/10.1159/000081480
  36. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. Cell Biochem Funct 2006;24:353-356. https://doi.org/10.1002/cbf.1227

피인용 문헌

  1. HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? vol.15, pp.4, 2018, https://doi.org/10.2174/1573397115666190115143226
  2. Behсet's disease: clinical and gender associations vol.13, pp.2, 2019, https://doi.org/10.14412/1996-7012-2019-2-84-89
  3. Behçet’s disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature vol.38, pp.9, 2018, https://doi.org/10.1007/s10067-019-04570-w
  4. Behcet’s disease in Iran: Analysis of 7641 cases vol.29, pp.6, 2018, https://doi.org/10.1080/14397595.2018.1558752
  5. Past and Present Behçet’s Disease Animal Models vol.21, pp.None, 2018, https://doi.org/10.2174/1389450121666200719010425
  6. Male Sex Is a Significant Predictor of All-cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis vol.36, pp.18, 2021, https://doi.org/10.3346/jkms.2021.36.e120
  7. The relationship between non‐segmental Vitiligo, HLA genotype and oxidative stress vol.75, pp.3, 2018, https://doi.org/10.1111/ijcp.14024
  8. Central sensitization and its relationship with health profile in Behçet’s disease vol.31, pp.2, 2021, https://doi.org/10.1080/14397595.2020.1780076
  9. Behcet’s Disease in Southeast Asia. Clinical Features, Genetic Study, and Review of Recent Treatment vol.21, pp.1, 2018, https://doi.org/10.1142/s2661341721300020
  10. Epidemiologic and Etiological Features of Korean Patients With Behçet's Disease vol.28, pp.4, 2021, https://doi.org/10.4078/jrd.2021.28.4.183
  11. Significant Decline in the Incidence of Behçet’s Disease in South Korea: A Nationwide Population‐Based Study (2004-2017) vol.73, pp.11, 2018, https://doi.org/10.1002/acr.24408
  12. Clinical phenotypes of Behçet’s syndrome in a large cohort of Italian patients: focus on gender differences vol.50, pp.6, 2018, https://doi.org/10.1080/03009742.2021.1885735
  13. Patient characteristics in Behçet’s Syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases vol.51, pp.1, 2022, https://doi.org/10.1080/03009742.2021.1904622